NOVELTY – A functional liposomal configuration comprising particles with a maximum diameter of 2 micrometers and comprising: (a) a ternary lipid system composed of a cationic lipid, a structural lipid and a helper lipid; and (b) a polynucleotide, is new. USE – The configuration and methods are useful for producing a liposomal gene vaccine (claimed) for preventing and treating tuberculosis. ADVANTAGE – The invention has high transfection efficiency. DETAILED DESCRIPTION – INDEPENDENT CLAIMS are: (1) a method for obtaining a functional liposomal configuration; (2) a method for producing a liposomal gene vaccine developed by means of the plasmid vaccinal construct, naked plasmid (pVAX1), containing DNA-heat shock protein 65 (Hsp65) carried in liposomes composed of the functional lipids egg phosphatidylcholine (EPC), dioleoyl phosphatidylethanolamine (DOPE) and 1,2-Dioleoyl-3-Trimethylammonium-Propane (DOTAP) at a molar ratio of 25% of cationic lipid (DOTAP), 50% of structural lipid (EPC), and 25% of helper lipid (DOPE), containing DNA preferably located on the surface; and (3) a liposomal gene vaccine (LIPO-DNA-Hsp65), obtained comprising complexing functional liposomes with approximately 25 mu g of the plasmid DNA-Hsp65, having a functional potential against tuberculosis and other microbacterial infections, not requiring the addition of immunostimulators, having high efficacy when administered nasally, the mean diameter of the colloidal particles having a size on the order of nanometers up to 1-2 micrometers.
B07 (General – tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.); D16 (Fermentation industry – including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.); B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.)